We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
PURITAN MEDICAL

Download Mobile App





Latest Generation Random Analyzer System Unveiled at the AACC Clinical Lab Expo

By LabMedica International staff writers
Posted on 01 Aug 2013
Print article
Image: The Siemens VersaCell X3 System (Photo courtesy of Siemens).
Image: The Siemens VersaCell X3 System (Photo courtesy of Siemens).
The latest generation random access clinical chemistry and immunochemistry analyzer is receiving its debut at the AACC (American Association for Clinical Chemistry) Clinical Lab Expo in Houston (TX, USA), from July 30-August 1, 2013.

The Siemens Healthcare Diagnostics (Tarrytown, NY, USA) is unveiling the advanced VersaCell X3 system at the Clinical Lab Expo.

The newest model of Siemens’s longstanding VersaCell System, the new VersaCell X3 Solution now offers the benefits of automation without the space or budget considerations of a track-based system. VersaCell X3 Solution’s arrival compliments the recent launch of the Siemens Aptio Automation platform, designed for the growing needs of medium- to very high-volume laboratories.

The VersaCell X3 Solution delivers several advantages. The new platform maintains its small footprint and upright design, but now connects up to three Siemens analyzers through a single robotic sample interface for increased productivity gains. By supporting a customized mix of chemistry, immunoassay and/or integrated systems and associated assay menus, VersaCell X3 Solution helps labs to reduce operator sample handling, better prioritize staff work and eliminate pre- and post-analytical processing—all through one-touch sample management.

A new priority drawer on the VersaCell X3 Solution provides eight new STAT positions and frees up 50 sample positions for routine processing, enhancing STAT management and increasing overall sample routing flexibility. Modifications to VersaCell X3 Solution’s signature robotic arm also enable it to support both rounded and flat-bottom tubes, and the incorporation of a docking plate reduces service intervention time for all connected systems. A centralized screen on VersaCell X3 Solution provides consolidated, single-operator access to all connected analyzers, and further data consolidation is achievable through a connection to Siemens’ CentraLink Data Management System.

“Siemens strives to be a trusted partner for labs of all sizes and central to that goal is helping them identify and capitalize on their workflow excellence potential,” said Dave Hickey, CEO of the IT Business Unit at Siemens Healthcare Diagnostics. “The introduction of VersaCell X3 Solution is yet another way Siemens delivers on this mission through its ability to help labs streamline nonautomated environments and enhance operational efficiency, all at a cost they can justify.”

Related Links:
Siemens Healthcare Diagnostics

Platinum Member
COVID-19 Rapid Test
OSOM COVID-19 Antigen Rapid Test
Magnetic Bead Separation Modules
MAG and HEATMAG
Complement 3 (C3) Test
GPP-100 C3 Kit
Gold Member
Fully Automated Cell Density/Viability Analyzer
BioProfile FAST CDV

Print article

Channels

Clinical Chemistry

view channel
Image: The 3D printed miniature ionizer is a key component of a mass spectrometer (Photo courtesy of MIT)

3D Printed Point-Of-Care Mass Spectrometer Outperforms State-Of-The-Art Models

Mass spectrometry is a precise technique for identifying the chemical components of a sample and has significant potential for monitoring chronic illness health states, such as measuring hormone levels... Read more

Molecular Diagnostics

view channel
Image: A blood test could predict lung cancer risk more accurately and reduce the number of required scans (Photo courtesy of 123RF)

Blood Test Accurately Predicts Lung Cancer Risk and Reduces Need for Scans

Lung cancer is extremely hard to detect early due to the limitations of current screening technologies, which are costly, sometimes inaccurate, and less commonly endorsed by healthcare professionals compared... Read more

Hematology

view channel
Image: The CAPILLARYS 3 DBS devices have received U.S. FDA 510(k) clearance (Photo courtesy of Sebia)

Next Generation Instrument Screens for Hemoglobin Disorders in Newborns

Hemoglobinopathies, the most widespread inherited conditions globally, affect about 7% of the population as carriers, with 2.7% of newborns being born with these conditions. The spectrum of clinical manifestations... Read more

Immunology

view channel
Image: Exosomes can be a promising biomarker for cellular rejection after organ transplant (Photo courtesy of Nicolas Primola/Shutterstock)

Diagnostic Blood Test for Cellular Rejection after Organ Transplant Could Replace Surgical Biopsies

Transplanted organs constantly face the risk of being rejected by the recipient's immune system which differentiates self from non-self using T cells and B cells. T cells are commonly associated with acute... Read more

Pathology

view channel
Image: Comparison of traditional histopathology imaging vs. PARS raw data (Photo courtesy of University of Waterloo)

AI-Powered Digital Imaging System to Revolutionize Cancer Diagnosis

The process of biopsy is important for confirming the presence of cancer. In the conventional histopathology technique, tissue is excised, sliced, stained, mounted on slides, and examined under a microscope... Read more
Copyright © 2000-2024 Globetech Media. All rights reserved.